<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01884415</url>
  </required_header>
  <id_info>
    <org_study_id>HEPATOTRAS</org_study_id>
    <nct_id>NCT01884415</nct_id>
  </id_info>
  <brief_title>Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis</brief_title>
  <official_title>Open-label, Phase III, Randomized, Clinical Trial to Evaluate the Efficacy of Two Different Hepatitis B Virus (HBV) Vaccination Schemes in Patients With Hepatic Cirrhosis Candidates to Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial is to compare the response rate obtained with two
      different vaccination schemes against HBV in cirrhotic patients. These patients must be
      candidates for liver transplantation, who have failed seroconversion (anti-HBs &lt; 10 IU/ml)
      after three intramuscular doses of 40 µg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 7, 2012</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-vaccination serological response</measure>
    <time_frame>At 35 ± 5 days after administration</time_frame>
    <description>To compare the response rate obtained with two different vaccination schemes against HBV in cirrhotic patients potential candidates for liver transplantation, who have failed seroconversion (anti-HBs &lt; 10 IU/ml) after three intramuscular doses of 40 µg at 0, 1 and 2 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of serological response to HBV vaccination to etiology and severity of cirrhosis</measure>
    <time_frame>After 6 months</time_frame>
    <description>Etiology and severity of cirrhosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of serological response to HBV vaccination to diabetes presence</measure>
    <time_frame>After 6 months</time_frame>
    <description>Diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of serological response to HBV vaccination to body mass index</measure>
    <time_frame>At baseline</time_frame>
    <description>Body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of serological response to HBV vaccination to anti-Hepatitis B core antigen positive presence</measure>
    <time_frame>At baseline</time_frame>
    <description>Presence of anti-Hepatitis B core antigen positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of serological response to HBV vaccination to obesity</measure>
    <time_frame>After 6 months</time_frame>
    <description>Obesity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Cirrhosis</condition>
  <condition>Awaiting Organ Transplant</condition>
  <arm_group>
    <arm_group_label>Second HBV vaccination cycle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second cycle of HBV vaccination (0, 1 and 2 months)will be administered. Three intramuscular doses of 40 µg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of HBV vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose (40µg) of HBV vaccine will be administered at 6 months after 1 cycle of HBV vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBV vaccine</intervention_name>
    <description>Patients receive a second cycle of vaccination</description>
    <arm_group_label>Second HBV vaccination cycle</arm_group_label>
    <other_name>HBVAXPRO 40µg HBV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBV vaccine</intervention_name>
    <description>Patients receive vaccination according to the guidelines.</description>
    <arm_group_label>Single dose of HBV vaccine</arm_group_label>
    <other_name>HBVAXPRO 40µg HBV vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cirrhotic patients, potential candidates for liver transplantation, with indication to
             HBV vaccination (HBsAg negative and anti-HBs negative).

          2. Patients under treatment with HBVAXPRO® who do not show a response after the first
             cycle of vaccination of three intramuscular doses of 40 µg at 0, 1 and 2 months.

          3. Patients over 18 years old.

          4. Negative pregnancy test.

          5. Patients who have given their consent to participate in the study.

        Exclusion Criteria:

          1. Absolute contraindication to HBV vaccine.

          2. Medical history of allergy to any component of the vaccine.

          3. Chronic renal failure on hemodialysis.

          4. Presence of antibodies against Human Immunodeficiency Virus.

          5. Patients with seroconversion (anti-HBs &gt; 10 IU /ml) after the first three doses of
             vaccine.

          6. Lack of consent to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Manual Pascasio Acevedo, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Virgen del Rocío Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virgen del Rocío Hospital</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2013</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

